Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
Mario Balsa, medical oncology resident at Institut Català d’Oncologia, shared an insightful post on X:
” ‘New’ The New England Journal of Medicine (NEJM) study in 1,766 patients with cancer-associated VTE:
- Reduced-dose apixaban (2.5mg BID) vs full dose (5mg BID)
- VTE recurrence: 2.1% vs 2.8%
- Clinically relevant bleeding: 12.1% vs 15.6%
Same protection, less bleeding. Sometimes, less really is more!”
Effects of reduced dose of an oral anticoagulant on thromboembolic events and bleeding are discussed in the new study ”Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism” published by Isabelle Mahé et al. in the New England Journal of Medicine (NEJM).
In patients with active cancer and venous thromboembolism, extended treatment with reduced-dose apixaban was as effective as the full dose in preventing recurrent events.
Moreover, dose reduction resulted in fewer bleeding complications.
This supports reduced-dose apixaban as a safer alternative for long-term anticoagulation in this population.
Never miss the scientific advancements in the World of Hematology, read Hemostasis Today.
-
Sep 4, 2025, 02:53Chokri Ben Lamine on Iron Deficiency Without Anemia (IDWA): Symptoms, Diagnosis, and Management Tips
-
Sep 2, 2025, 13:59No Added Benefit of Surgery Within 72 Hours for Intracerebral Hemorrhage
-
Sep 2, 2025, 13:57DCB Technical Mastery Webinar by SCAI: European Best Practices for Complex Coronary Lesions
-
Sep 2, 2025, 13:51Zack Wheeler’s DVT Diagnosis Highlights Thoracic Outlet Syndrome Risks in Athletes: National Blood Clot Alliance
-
Sep 2, 2025, 13:39Heparins Outperform DOACs and FXII/FXI Inhibitors in Preventing Thrombin Generation: JTH Study
-
Sep 4, 2025, 07:58Flora Peyvandi: LRRC8 Complexes Control Platelet Function and Arterial Thrombosis
-
Sep 3, 2025, 20:04Aymeric Couturier Shares Recent Studies on Anticoagulation and Atrial Fibrillation in Dialysis
-
Sep 3, 2025, 19:34Evidence Gap in von Willebrand Disease: Commentary from Nathan Connell and Colleagues
-
Sep 3, 2025, 19:18Archil Jaliashvili: Novel Rescue in Hyperhaemolysis Syndrome of Sickle Cell Anaemia
-
Sep 3, 2025, 18:38Dirk Sibbing Shares a Recent ''Excellent Study'' on Clopidogrel Versus Aspirin by Marco Valgimigli and Colleagues
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 3, 2025, 14:18Living with Factor V Deficiency: Helen’s Inspiring Story on Haemnet Haemcast
-
Sep 3, 2025, 14:11Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
-
Sep 3, 2025, 14:00Jacek Lesinski: The Importance of Whole Blood and Plasma Donation
-
Sep 2, 2025, 14:02King Felipe VI Highlights Global Challenge of Cardiovascular Health at ESC Congress 2025
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery